Leman Biotech and the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine have entered into a clinical trial collaboration agreement on the safety and efficacy of the metabolism-enhanced CD19 CAR-T cell injection (Meta10-19 CAR-T) in treating relapsed or refractory diffuse large B-cell lymphoma.
Based on the proprietary core technology of Meta 10 owned by Leman Biotech, the R&D team at Leman Biotech has developed the metabolism-enhanced CD19 CAR-T (Meta10-19 CAR-T), which has demonstrated impressive anti-tumor effects in multiple mouse tumor models. The therapy has the ability to produce a significant amount of immune memory cells to prevent tumor recurrence and may be a highly promising solution for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Diffuse large B-cell lymphoma is the most common type of lymphoma for adults, accounting for a significant portion of non-Hodgkin lymphoma cases, particularly in Asia. Conventional CD19 CAR-T therapies has a complete response rate of 40% to 50% for relapsed or refractory cases, but almost half of those patients experience a relapse within a year. Thus, there is a urgent need to develop new CAR-T cell therapies to increase the patient response rates and reduce the rate of recurrence.
Professor Huang is a renowned expert in the field of hematology, the Director of the Zhejiang University Institute of Hematology, and the Director of the Zhejiang Center of Stem Cell and Cell Immunotherapy. He is highly regarded in the hematology community and has received recognition for his work, including twice winning the National Science and Technology Progress Award. He is an expert in the diagnosis and treatment of hematologic malignant diseases, including acute and chronic leukemia, lymphoma, multiple myeloma, and more. With his deep knowledge and innovative approach to treatment planning, Professor Huang is well-equipped to contribute to the success of the clinical trial research.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
